Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-04-01

Target enrollment:

Participant gender:

This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months

PHASE3

Arthrosi Therapeutics